A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Defibrotide (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms DEFACOVID
Most Recent Events
- 06 Jun 2023 Status changed from recruiting to completed.
- 15 Feb 2023 Planned End Date changed from 30 Jun 2022 to 31 May 2023.
- 28 Jun 2022 Preliminary safety results presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022